This controversy is also entering the field of NSCLC ALK testing [7], with an increasing number of recent publications addressing discordances between in situ hybridization and IHC assays [8]–[14], further fuelled by the different regulatory approvals and the arrival of other ALK inhibitors [3], [15]. This evidence concerns the gene ALK and non-small cell lung carcinoma.